STOCK TITAN

[144] 10x Genomics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

10x Genomics (TXG) Form 144 notice shows a proposed sale of 22,037 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $295,516.17 and an approximate sale date of 08/22/2025 on NASDAQ. The filing reports the shares were acquired as a Restricted Stock Unit grant on 08/21/2025 with 61,587 units noted as acquired and payment described as Services Rendered. It also discloses a prior sale by the same person of 4,044 shares on 05/22/2025 for gross proceeds of $33,562.37. The filer affirms no undisclosed material adverse information.

Avviso Form 144 di 10x Genomics (TXG) indica una proposta di vendita di 22.037 azioni ordinarie tramite Morgan Stanley Smith Barney, per un valore complessivo di mercato di $295.516,17 e con data di vendita approssimativa 22/08/2025 su NASDAQ. La comunicazione riporta che le azioni sono state acquisite come concessione di Restricted Stock Unit il 21/08/2025, con 61.587 unità annotate come acquisite e pagamento descritto come Servizi Resi. Viene inoltre resa nota una precedente vendita da parte della stessa persona di 4.044 azioni il 22/05/2025 per proventi lordi di $33.562,37. Il dichiarante conferma l'assenza di informazioni materiali sfavorevoli non divulgate.

Aviso Form 144 de 10x Genomics (TXG) muestra una propuesta de venta de 22.037 acciones ordinarias a través de Morgan Stanley Smith Barney, con un valor de mercado agregado de $295.516,17 y una fecha aproximada de venta el 22/08/2025 en NASDAQ. La presentación informa que las acciones fueron adquiridas como una concesión de Restricted Stock Unit el 21/08/2025, con 61.587 unidades anotadas como adquiridas y el pago descrito como Servicios Prestados. También divulga una venta anterior por parte de la misma persona de 4.044 acciones el 22/05/2025 por ingresos brutos de $33.562,37. El declarante afirma que no existen informaciones adversas materiales no divulgadas.

10x Genomics (TXG) Form 144 통지는 Morgan Stanley Smith Barney를 통해 22,037 보통주를 매도할 예정임을 나타내며, 총 시장 가치는 $295,516.17이고 대략적인 매각일은 2025/08/22로 NASDAQ에 기재되어 있습니다. 제출서류는 해당 주식들이 제한주식단위(Restricted Stock Unit) 부여2025/08/21에 취득되었음을 보고하며, 61,587 단위가 취득으로 기재되고 지급 사유는 제공된 서비스로 설명되어 있습니다. 또한 동일인이 2025/05/224,044주를 매각하여 총수익 $33,562.37을 올린 이전 거래도 공개하고 있습니다. 제출인은 공개되지 않은 중대한 불리한 정보가 없음을 확인합니다.

Avis Form 144 de 10x Genomics (TXG) indique une proposition de vente de 22 037 actions ordinaires via Morgan Stanley Smith Barney, pour une valeur de marché totale de $295 516,17 et une date de vente approximative le 22/08/2025 sur NASDAQ. Le dépôt signale que les actions ont été acquises en tant que Restricted Stock Unit grant le 21/08/2025, avec 61 587 unités notées comme acquises et le paiement décrit comme Services Rendus. Il divulgue également une vente antérieure par la même personne de 4 044 actions le 22/05/2025 pour un produit brut de $33 562,37. Le déclarant affirme l'absence d'informations défavorables importantes non divulguées.

Form 144-Mitteilung von 10x Genomics (TXG) weist auf einen geplanten Verkauf von 22.037 Stammaktien über Morgan Stanley Smith Barney hin, mit einem aggregierten Marktwert von $295.516,17 und einem ungefähren Verkaufsdatum 22.08.2025 an der NASDAQ. Die Einreichung berichtet, dass die Aktien am 21.08.2025 als Restricted Stock Unit-Zuteilung erworben wurden, wobei 61.587 Einheiten als erworben vermerkt sind und die Gegenleistung als erbrachte Dienstleistungen beschrieben wird. Es wird außerdem ein früherer Verkauf derselben Person von 4.044 Aktien am 22.05.2025 für Bruttoerlöse von $33.562,37 offengelegt. Der Einreicher bestätigt, dass keine nicht offen gelegten, wesentlichen nachteiligen Informationen vorliegen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Insider plans to sell 22,037 shares (value $295.5k) from an RSU grant received one day earlier; prior small sale of 4,044 shares noted.

The filing documents a routine Rule 144 notice for the sale of common stock through a broker, indicating the shares originate from a restricted stock unit grant dated 08/21/2025 and are to be sold on 08/22/2025. The disclosure includes a recent small sale on 05/22/2025, suggesting ongoing insider liquidity activity but does not provide context on ownership percentage or company-wide impact. No financial performance data or forward-looking statements are included.

TL;DR: Filing is a standard Rule 144 notification; signer attests no undisclosed material information and references a services-based RSU payment.

The notice follows regulatory requirements by identifying the broker, share counts, acquisition method (RSU grant), and recent disposals. The signing representation about material information and the inclusion of prior sales meet disclosure norms. The document does not reveal governance changes, contracts, or material events beyond the securities transactions.

Avviso Form 144 di 10x Genomics (TXG) indica una proposta di vendita di 22.037 azioni ordinarie tramite Morgan Stanley Smith Barney, per un valore complessivo di mercato di $295.516,17 e con data di vendita approssimativa 22/08/2025 su NASDAQ. La comunicazione riporta che le azioni sono state acquisite come concessione di Restricted Stock Unit il 21/08/2025, con 61.587 unità annotate come acquisite e pagamento descritto come Servizi Resi. Viene inoltre resa nota una precedente vendita da parte della stessa persona di 4.044 azioni il 22/05/2025 per proventi lordi di $33.562,37. Il dichiarante conferma l'assenza di informazioni materiali sfavorevoli non divulgate.

Aviso Form 144 de 10x Genomics (TXG) muestra una propuesta de venta de 22.037 acciones ordinarias a través de Morgan Stanley Smith Barney, con un valor de mercado agregado de $295.516,17 y una fecha aproximada de venta el 22/08/2025 en NASDAQ. La presentación informa que las acciones fueron adquiridas como una concesión de Restricted Stock Unit el 21/08/2025, con 61.587 unidades anotadas como adquiridas y el pago descrito como Servicios Prestados. También divulga una venta anterior por parte de la misma persona de 4.044 acciones el 22/05/2025 por ingresos brutos de $33.562,37. El declarante afirma que no existen informaciones adversas materiales no divulgadas.

10x Genomics (TXG) Form 144 통지는 Morgan Stanley Smith Barney를 통해 22,037 보통주를 매도할 예정임을 나타내며, 총 시장 가치는 $295,516.17이고 대략적인 매각일은 2025/08/22로 NASDAQ에 기재되어 있습니다. 제출서류는 해당 주식들이 제한주식단위(Restricted Stock Unit) 부여2025/08/21에 취득되었음을 보고하며, 61,587 단위가 취득으로 기재되고 지급 사유는 제공된 서비스로 설명되어 있습니다. 또한 동일인이 2025/05/224,044주를 매각하여 총수익 $33,562.37을 올린 이전 거래도 공개하고 있습니다. 제출인은 공개되지 않은 중대한 불리한 정보가 없음을 확인합니다.

Avis Form 144 de 10x Genomics (TXG) indique une proposition de vente de 22 037 actions ordinaires via Morgan Stanley Smith Barney, pour une valeur de marché totale de $295 516,17 et une date de vente approximative le 22/08/2025 sur NASDAQ. Le dépôt signale que les actions ont été acquises en tant que Restricted Stock Unit grant le 21/08/2025, avec 61 587 unités notées comme acquises et le paiement décrit comme Services Rendus. Il divulgue également une vente antérieure par la même personne de 4 044 actions le 22/05/2025 pour un produit brut de $33 562,37. Le déclarant affirme l'absence d'informations défavorables importantes non divulguées.

Form 144-Mitteilung von 10x Genomics (TXG) weist auf einen geplanten Verkauf von 22.037 Stammaktien über Morgan Stanley Smith Barney hin, mit einem aggregierten Marktwert von $295.516,17 und einem ungefähren Verkaufsdatum 22.08.2025 an der NASDAQ. Die Einreichung berichtet, dass die Aktien am 21.08.2025 als Restricted Stock Unit-Zuteilung erworben wurden, wobei 61.587 Einheiten als erworben vermerkt sind und die Gegenleistung als erbrachte Dienstleistungen beschrieben wird. Es wird außerdem ein früherer Verkauf derselben Person von 4.044 Aktien am 22.05.2025 für Bruttoerlöse von $33.562,37 offengelegt. Der Einreicher bestätigt, dass keine nicht offen gelegten, wesentlichen nachteiligen Informationen vorliegen.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for TXG disclose about the proposed sale?

The Form 144 discloses a proposed sale of 22,037 shares of TXG common stock valued at $295,516.17, to be sold on or about 08/22/2025 on NASDAQ through Morgan Stanley Smith Barney.

How were the shares being sold acquired according to the filing?

The shares were acquired as a Restricted Stock Unit grant on 08/21/2025; the filing lists 61,587 units acquired and indicates Services Rendered as the nature of payment.

Does the Form 144 show any recent sales by the same person?

Yes. The filing reports a prior sale of 4,044 shares on 05/22/2025 that generated gross proceeds of $33,562.37.

Which broker is handling the proposed sale listed in the Form 144?

The broker named is Morgan Stanley Smith Barney LLC Executive Services, with an address in Sandy, UT.

Does the filer attest to any undisclosed material information?

The filer signs a representation that they do not know any material adverse information regarding the issuer that has not been publicly disclosed.
10X Genomics, Inc.

NASDAQ:TXG

TXG Rankings

TXG Latest News

TXG Latest SEC Filings

TXG Stock Data

1.66B
112.26M
1.87%
105.23%
11.61%
Health Information Services
Laboratory Analytical Instruments
Link
United States
PLEASANTON